Ankündigung • Jun 30
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2026 Results on Aug 26, 2026 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report first half, 2026 results on Aug 26, 2026 Reported Earnings • May 01
First quarter 2026 earnings released: CN¥0.04 loss per share (vs CN¥0.059 loss in 1Q 2025) First quarter 2026 results: CN¥0.04 loss per share (improved from CN¥0.059 loss in 1Q 2025). Revenue: CN¥652.1m (up 20% from 1Q 2025). Net loss: CN¥14.8m (loss narrowed 33% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Ankündigung • Apr 20
Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 08, 2026 Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 08, 2026, at 14:30 China Standard Time. Location: No. 1, Jianye Road, ?China-Singapore Suzhou-Chuzhou Hi-tech Development Zone, Chuzhou, Anhui China Ankündigung • Mar 31
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q1, 2026 Results on Apr 30, 2026 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Ankündigung • Dec 31
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2025 Results on Mar 31, 2026 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report fiscal year 2025 results on Mar 31, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: CN¥0.086 loss per share (vs CN¥0.12 loss in 3Q 2024) Third quarter 2025 results: CN¥0.086 loss per share (improved from CN¥0.12 loss in 3Q 2024). Revenue: CN¥633.5m (up 9.7% from 3Q 2024). Net loss: CN¥32.4m (loss narrowed 29% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 21% per year. Ankündigung • Sep 30
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q3, 2025 Results on Oct 25, 2025 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q3, 2025 results on Oct 25, 2025 Ankündigung • Jul 02
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2025 Results on Aug 28, 2025 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.2% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). New Risk • May 07
New major risk - Revenue and earnings growth Earnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Ankündigung • Apr 29
Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 22, 2025 Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 22, 2025, at 14:00 China Standard Time. Ankündigung • Mar 31
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q1, 2025 Results on Apr 29, 2025 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Ankündigung • Dec 31
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2024 Results on Mar 28, 2025 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Nov 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥861m free cash flow). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.11 loss in 3Q 2023) Third quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.11 loss in 3Q 2023). Revenue: CN¥577.6m (up 144% from 3Q 2023). Net loss: CN¥45.7m (loss widened 3.0% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Ankündigung • Sep 30
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q3, 2024 Results on Oct 31, 2024 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 06
Second quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.20 loss in 2Q 2023) Second quarter 2024 results: CN¥0.32 loss per share (further deteriorated from CN¥0.20 loss in 2Q 2023). Revenue: CN¥470.9m (up 225% from 2Q 2023). Net loss: CN¥108.9m (loss widened 42% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Ankündigung • Jun 29
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2024 Results on Aug 06, 2024 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report first half, 2024 results on Aug 06, 2024 Reported Earnings • May 01
First quarter 2024 earnings released: CN¥0.082 loss per share (vs CN¥0.043 loss in 1Q 2023) First quarter 2024 results: CN¥0.082 loss per share (further deteriorated from CN¥0.043 loss in 1Q 2023). Revenue: CN¥378.1m (flat on 1Q 2023). Net loss: CN¥30.5m (loss widened 107% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Ankündigung • May 01
Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 23, 2024 Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: 6F, Suchu International Business Center, Chuzhou, Anhui China Ankündigung • Mar 30
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q1, 2024 results on Apr 30, 2024 New Risk • Feb 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥176m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Ankündigung • Dec 30
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 30, 2024 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report fiscal year 2023 results on Apr 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.006 loss in 3Q 2022) Third quarter 2023 results: CN¥0.11 loss per share (further deteriorated from CN¥0.006 loss in 3Q 2022). Revenue: CN¥236.5m (down 33% from 3Q 2022). Net loss: CN¥44.3m (loss widened CN¥42.5m from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CN¥52m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥52m free cash flow). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Aug 31
Second quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.004 profit in 2Q 2022) Second quarter 2023 results: CN¥0.20 loss per share (down from CN¥0.004 profit in 2Q 2022). Revenue: CN¥144.8m (down 68% from 2Q 2022). Net loss: CN¥76.9m (down CN¥78.5m from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Ankündigung • Aug 01
Jiangsu Lanfeng Bio-Chemical Co.,Ltd Approves Management Elections Jiangsu Lanfeng Bio-chemical Co.,Ltd at its Extraordinary General Meeting held on 28 July 2023 approved the election of Zheng Xu, Li Zhilei, Lu Zhonglin, Cui Haifeng and Li Shaohua as non-independent directors. The company approved the election of Yuan Jian, Liu Xingchong and Tang Jian as independent directors. The company approved the election of Han Yichen and Ren Junli as non-employee supervisors. New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥131m free cash flow). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Ankündigung • Jul 14
Zheng Xu acquired a 18.04% stake in Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) from Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. for approximately CNY 300 million. Zheng Xu sined a Share Transfer Agreement to acquire a 18.04% stake in Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) from Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. for approximately CNY 300 million on June 16, 2023. As part of the transaction, Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. transferring 34,334,137 and 33,123,295 shares, respectively, total of 18.04% stake, to Zheng Xu at CNY 4.41 per share.
Zheng Xu completed the acquisition of a 18.04% stake in Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) from Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. on July 10, 2023. Reported Earnings • Apr 28
Full year 2022 earnings released: CN¥0.88 loss per share (vs CN¥1.44 loss in FY 2021) Full year 2022 results: CN¥0.88 loss per share (improved from CN¥1.44 loss in FY 2021). Revenue: CN¥1.45b (flat on FY 2021). Net loss: CN¥320.7m (loss narrowed 35% from FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 4% per year. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Employee Supervisor Wen Chen is the most experienced director on the board, commencing their role in 2021. Independent Director Shaohua Li was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.076 loss in 3Q 2021) Third quarter 2022 results: CN¥0.006 loss per share (improved from CN¥0.076 loss in 3Q 2021). Revenue: CN¥354.2m (down 21% from 3Q 2021). Net loss: CN¥1.78m (loss narrowed 94% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • May 04
First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.004 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.004 in 1Q 2021). Revenue: CN¥438.9m (up 32% from 1Q 2021). Net income: CN¥881.0k (down 29% from 1Q 2021). Profit margin: 0.2% (down from 0.4% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors There are 9 new directors who have joined the board in the last 3 years. Deputy GM & Non-Independent Director Si Yu Gu was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 19
Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 10, 2022 Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 10, 2022, at 14:00 China Standard Time. Agenda: To consider the 2021 work report of the board of directors; to consider the 2021 work report of the supervisory committee; to consider the 2021 annual report and its summary; to consider the 2021 annual accounts; to consider the 2021 profit distribution plan; to consider the 2022 financial budget report; to consider the reappointment of 2022 audit firm; to consider the 2022 estimated continuing connected transactions; to consider the 2022 application for comprehensive credit line to financial institutions by the Company and its subsidiaries; and to consider the amendments to relevant systems of the company. Reported Earnings • Apr 17
Full year 2021 earnings released: CN¥1.44 loss per share (vs CN¥0.04 profit in FY 2020) Full year 2021 results: CN¥1.44 loss per share (down from CN¥0.04 profit in FY 2020). Revenue: CN¥1.44b (up 7.6% from FY 2020). Net loss: CN¥491.2m (down CN¥506.0m from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 23
Third quarter 2021 earnings released: CN¥0.076 loss per share (vs CN¥0.06 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CN¥445.3m (down 11% from 3Q 2020). Net loss: CN¥28.7m (down 240% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 20
Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.017 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: CN¥306.6m (down 9.9% from 2Q 2020). Net loss: CN¥14.7m (down 358% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥5.38, the stock trades at a trailing P/E ratio of 63.8x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 34% over the past three years. Reported Earnings • Apr 20
First quarter 2021 earnings released: EPS CN¥0.004 (vs CN¥0.05 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥333.7m (up 40% from 1Q 2020). Net income: CN¥1.24m (up CN¥16.6m from 1Q 2020). Profit margin: 0.4% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • Mar 09
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2020 Results on Apr 20, 2021 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report fiscal year 2020 results on Apr 20, 2021 Is New 90 Day High Low • Feb 04
New 90-day low: CN¥3.50 The company is down 15% from its price of CN¥4.10 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. Is New 90 Day High Low • Jan 12
New 90-day low: CN¥3.53 The company is down 17% from its price of CN¥4.25 on 14 October 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 15
New 90-day low: CN¥3.90 The company is down 1.0% from its price of CN¥3.92 on 16 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Nov 18
New 90-day high: CN¥4.37 The company is up 6.0% from its price of CN¥4.13 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥533.3m, with losses narrowing by 34% from the prior year. Total revenue was CN¥1.40b over the last 12 months, down 7.9% from the prior year. Ankündigung • Oct 17
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q3, 2020 Results on Oct 23, 2020 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report Q3, 2020 results on Oct 23, 2020 Is New 90 Day High Low • Oct 16
New 90-day high: CN¥4.30 The company is up 7.0% from its price of CN¥4.01 on 17 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period. Ankündigung • Sep 26
Taicang Yunzaifei Material Trading Co., Ltd. signed an agreement to acquire Taicang Lanfeng Chemical Co., Ltd. from Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) for CNY 10.8 million. Taicang Yunzaifei Material Trading Co., Ltd. signed an agreement to acquire Taicang Lanfeng Chemical Co., Ltd. from Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) for CNY 10.8 million on September 22, 2020. Taicang Yunzaifei Material Trading will deposit first payment of CNY 8.6 million within 3 working days after signing of the agreement to Jiangsu Lanfeng Bio-chemical. Ankündigung • Aug 02
Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2020 Results on Aug 25, 2020 Jiangsu Lanfeng Bio-chemical Co.,Ltd announced that they will report first half, 2020 results on Aug 25, 2020 
